TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36529145

Group type: EXPERIMENTAL
Intervention: KCd consolidation group (carfilzomib-cyclophosphamide-dexamethasone)
Number of subjects: 281

Group type: COMPARATOR
Intervention: HSCT group (autologous haematopoietic stem-cell transplantation)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: KCd induction and consolidation
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: KCd maintenance
Number of subjects: 281

Group type: COMPARATOR
Intervention: HSCT maintenance
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Overall treatment-related serious adverse events
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Treatment-emergent deaths during induction
Number of subjects: 281

Group type: COMPARATOR
Intervention: Treatment-emergent deaths during maintenance after HSCT
Number of subjects: 281
Study: 36529152

Group type: EXPERIMENTAL
Intervention: Sequential transarterial chemoembolisation (TACE) followed by stereotactic body radiotherapy (27·5-40·0 Gy in five fractions) and avelumab (10 mg/kg) administered 14 days after radiotherapy and every 2 weeks thereafter.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TACE followed by stereotactic body radiotherapy and avelumab.
Number of subjects: 33
Study: 36529417

Group type: EXPERIMENTAL
Intervention: Patient-reported flares
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Physician-reported flares
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Worsening in DAPSA
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Transition to flare state
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Agreement between definitions of worsening
Number of subjects: 222
Study: 36529613

Group type: EXPERIMENTAL
Intervention: RRx-001 + irinotecan (RxI)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Single-agent regorafenib (RegI)
Number of subjects: 34
Study: 36529709

Group type: EXPERIMENTAL
Intervention: IV lacosamide infusion (2-12 mg/kg/day or 100-600 mg/day; 15-60 minutes infusion)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: IV lacosamide infusion
Number of subjects: 103
Study: 36529781

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 6463

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement
Number of subjects: 6463
Study: 36529811

Group type: EXPERIMENTAL
Intervention: Dupilumab plus topical corticosteroids (200 mg for 5 kg to < 15 kg; 300 mg for 15 kg to < 30 kg) every 4 weeks for 16 weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo plus topical corticosteroids
Number of subjects: 161
Study: 36529836

Group type: EXPERIMENTAL
Intervention: Crizanlizumab (0.2-8 mg/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Number of subjects: 0
Study: 36529949

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study: 36529989

Group type: EXPERIMENTAL
Intervention: Extensive genomic analysis
Number of subjects: 188
Study: 36529993

Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy
Number of subjects: 1398

Group type: COMPARATOR
Intervention: High-intensity statin monotherapy
Number of subjects: 1398
Study: 36530003

Group type: EXPERIMENTAL
Intervention: Quality of maternal and newborn care (QMNC) during the COVID-19 pandemic
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Access to routine antenatal care
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Presence of a companion during childbirth
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Use of personal protective equipment by health workers
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Sufficiency of health workers
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Episiotomy rates in spontaneous vaginal births
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Treatment with dignity
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Suffering abuse during childbirth
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Informal payments made during childbirth
Number of subjects: 4817

Group type: EXPERIMENTAL
Intervention: Quality of maternal and newborn care index by country
Number of subjects: 4817
Study: 36530009

Group type: EXPERIMENTAL
Intervention: Elective cesarean
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Emergency cesarean
Number of subjects: 620

Group type: COMPARATOR
Intervention: Spontaneous vaginal birth (SVB)
Number of subjects: 620
Study: 36530007

Group type: EXPERIMENTAL
Intervention: Private facilities
Number of subjects: 25206

Group type: COMPARATOR
Intervention: Public facilities
Number of subjects: 25206
Study: 36530013

Group type: COMPARATOR
Intervention: 2020
Number of subjects: 2079

Group type: COMPARATOR
Intervention: 2021
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Group 1 (women who went into labor)
Number of subjects: 2079

Group type: COMPARATOR
Intervention: QMNC index
Number of subjects: 2079
Study: 36530383

Group type: EXPERIMENTAL
Intervention: WatchPAT sleep monitor for home-based sleep assessment, including detection of sleep apnea
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: VA mobile app Cognitive Behavioral Therapy for Insomnia (CBT-i Coach)
Number of subjects: 37
Study: 36530873

Group type: EXPERIMENTAL
Intervention: Prone Position (PP)
Number of subjects: 40
Study: 36531070

Group type: EXPERIMENTAL
Intervention: Nano-Pulse Stimulation™ (NPS™) therapy
Number of subjects: 30
Study: 36531168

Group type: EXPERIMENTAL
Intervention: Alternate-day fasting for 30 hours every other day for 6 weeks
Number of subjects: 23
Study: 36531460

Group type: EXPERIMENTAL
Intervention: Lactobacilli-loaded vaginal capsules (one capsule per day for 10 days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (one capsule per day for 10 days)
Number of subjects: 74
Study: 36531700

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium scoring (CAC) on standard of care non-contrast chest CT (NCCT) imaging
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium scoring (CAC)
Number of subjects: 193
Study: 36531733

Group type: EXPERIMENTAL
Intervention: Novel transthoracic echocardiographic (TTE) parameters including left ventricular ejection fraction (LVEF) ≤ 48% and ratios of LVEF and left atrial diameter (LAD) ≤ 1.1
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) ≤ 48%
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Ratios of LVEF and left atrial diameter (LAD) ≤ 1.1
Number of subjects: 3109
Study: 36531736

Group type: EXPERIMENTAL
Intervention: Infarct-related artery (IRA)-IMR assessment after successful primary percutaneous coronary angioplasty (PPCI)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Higher IMR values
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Composite of cardiovascular death, re-infarction, re-hospitalization for heart failure, resuscitation or appropriate ICD shock at 1-year follow-up
Number of subjects: 242
Study: 36531900

Group type: EXPERIMENTAL
Intervention: Maintenance tobramycin inhalation solution (TIS) once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36532014

Group type: EXPERIMENTAL
Intervention: CD19-directed Piggy Bac CAR T cell therapy (pbCAR-T)
Number of subjects: 1
Study: 36532031

Group type: EXPERIMENTAL
Intervention: ChAd63 MVA ME-TRAP vaccine
Number of subjects: 0
Study: 36532058

Group type: EXPERIMENTAL
Intervention: Single dose of subcutaneous atacicept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly administrations of atacicept for one year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single administration of atacicept
Number of subjects: 0
Study: 36532191

Group type: EXPERIMENTAL
Intervention: Excessive screen time during COVID-19 lockdown
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Increased screen time since COVID-19 pandemic
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Age-related screen time
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Risk factors for excessive screen time in children
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Risk factors for excessive screen time in adolescents
Number of subjects: 249
Study: 36532545

Group type: EXPERIMENTAL
Intervention: 2.4 g eicosapentaenoic acid (EPA) + 1.2 g docosahexaenoic acid (DHA)/day for 6 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Observation for 6 months
Number of subjects: 49
Study: 36532582

Group type: EXPERIMENTAL
Intervention: Photosynthetic scaffold for dermal regeneration, illuminated to promote local oxygen production, followed by autograft implantation.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dermal vacuum massage therapy (as an adjunct to the main intervention).
Number of subjects: 1
Study: 36532775

Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 0
Study: 36533429

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (cisplatin + 5-fluorouracil or capecitabine)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Chemotherapy (control)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 187
Study: 36533519

Group type: EXPERIMENTAL
Intervention: Tasso+ centrifuged samples
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tasso+ whole blood samples
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard venipuncture
Number of subjects: 36
Study: 36533520

Group type: EXPERIMENTAL
Intervention: Posthospitalization behaviors
Number of subjects: 550
Study: 36533622

Group type: EXPERIMENTAL
Intervention: Standard medical treatment plus endovascular treatment (EVT)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 572
Study: 36533626

Group type: EXPERIMENTAL
Intervention: Supervised Exercise Therapy (SET), 3 times weekly for 6 months (maximum 77 sessions)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 272
Study: 36533748

Group type: EXPERIMENTAL
Intervention: AMD patients with various stages of AMD (stage 2 and stage 3)
Number of subjects: 458
Study: 36533797

Group type: EXPERIMENTAL
Intervention: Hands-free bipolar radiofrequency device; 3 total treatments to the chin and cheeks, spaced 2 weeks apart.
Number of subjects: 87
Study: 36533798

Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA-lanm for injection (DAXI) 40U (glabellar), 32U (forehead), 48U (lateral canthal)
Number of subjects: 48
Study: 36533856

Group type: EXPERIMENTAL
Intervention: Circulating ASCs in primary SS patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mature phenotype of ASCs in primary SS patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Inflammatory CXCR3+ phenotype of ASCs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Higher maturity index of ASCs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Frequency and/or maturity of ASCs
Number of subjects: 21
Study: 36533915

Group type: EXPERIMENTAL
Intervention: Early ECG abnormalities (major and minor)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Major early ECG abnormalities
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Age, preexisting ultimately fatal comorbidity, and cerebral insult as the cause of SE
Number of subjects: 155
Study: 36533948

Group type: EXPERIMENTAL
Intervention: Adjuvanted, inactivated vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza virus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccines without adjuvant
Number of subjects: 0
Study: 36534160

Group type: EXPERIMENTAL
Intervention: Lete-cel alone (arm 1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lete-cel with pembrolizumab (arm 2)
Number of subjects: 6
Study: 36534165

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 36534208

Group type: EXPERIMENTAL
Intervention: Tofacitinib plus MTX
Number of subjects: 530

Group type: COMPARATOR
Intervention: Tofacitinib monotherapy
Number of subjects: 530
Study: 36534217

Group type: EXPERIMENTAL
Intervention: Presence of macrophages
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Small minimum lumen area
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Large lipid arc (> 180°)
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Thin fibrous cap and large macrophage infiltration (> 67°)
Number of subjects: 1003
Study: 36534268

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36534274

Group type: EXPERIMENTAL
Intervention: Ofatumumab 20 mg subcutaneously
Number of subjects: 284
Study: 36534365

Group type: EXPERIMENTAL
Intervention: Therapeutic education and physical activity (TEPA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (CG) - received two educational group sessions on fatigue and physical activity
Number of subjects: 46
Study: 36534451

Group type: EXPERIMENTAL
Intervention: Semaglutide treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 36534461

Group type: EXPERIMENTAL
Intervention: Automated screening using natural language processing (NLP) for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual screening by nurses and social workers for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual screening
Number of subjects: 0
Study: 36534474

Group type: EXPERIMENTAL
Intervention: Immediate initiation of antibiotics after culture
Number of subjects: 186

Group type: COMPARATOR
Intervention: Specimen-initiated antibiotic protocol
Number of subjects: 186
Study: 36534492

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (Passive Recovery)
Number of subjects: 47
Study: 36534493

Group type: EXPERIMENTAL
Intervention: cAngio-IMR (contrast-flow angio-IMR)
Number of subjects: 104

Group type: COMPARATOR
Intervention: thermo-IMR (thermodilution-derived IMR)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: cAngio-IMR
Number of subjects: 104
Study: 36534647

Group type: EXPERIMENTAL
Intervention: Benznidazole (Bz)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Nifurtimox (Nf)
Number of subjects: 234
Study: 36534665

Group type: EXPERIMENTAL
Intervention: Personalized auditory training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpersonalized Active Control program
Number of subjects: 0
Study: 36534705

Group type: EXPERIMENTAL
Intervention: Population heterogeneity analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model fitting and data analysis
Number of subjects: 0
Study: 36534717

Group type: EXPERIMENTAL
Intervention: 3% 2-chloroprocaine (CP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:200,000 epinephrine and sodium bicarbonate (LEB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg administered after delivery
Number of subjects: 40
Study: 36534825

Group type: EXPERIMENTAL
Intervention: IFX s.c. 120 mg every 2 weeks
Number of subjects: 343

Group type: COMPARATOR
Intervention: IFX i.v. 3 mg/kg every 8 weeks
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: IFX s.c. post-switch
Number of subjects: 343

Group type: COMPARATOR
Intervention: IFX i.v. post-switch
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: IFX s.c. and i.v. (both)
Number of subjects: 343
Study: 36534910

Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 9088

Group type: COMPARATOR
Intervention: Hispanic patients
Number of subjects: 9088

Group type: EXPERIMENTAL
Intervention: White patients
Number of subjects: 9088
Study: 36534942

Group type: EXPERIMENTAL
Intervention: Crizotinib (CZ) with chemotherapy
Number of subjects: 66
Study: 36534976

Group type: EXPERIMENTAL
Intervention: DART (Decision-Aid for Renal Therapy)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 36535011

Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: rh-TPO
Number of subjects: 96
Study: 36535116

Group type: EXPERIMENTAL
Intervention: Sertraline plus olanzapine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 126
Study: 36535196

Group type: EXPERIMENTAL
Intervention: Short course radiotherapy (5 × 5 Gy in one week)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Chemoradiotherapy (50 Gy, 2 Gy/f, 5 weeks with capecitabine: 800 mg/m2)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Short course radiotherapy and Chemoradiotherapy
Number of subjects: 103
Study: 36535300

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg daily
Number of subjects: 296

Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 296

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 296
Study: 36535524

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 or 300 mg every 2 weeks up to 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36535535

Group type: EXPERIMENTAL
Intervention: Venglustat 8mg
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Venglustat 15mg
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Venglustat 8mg or 15mg
Number of subjects: 478
Study: 36535606

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 318

Group type: COMPARATOR
Intervention: Attention/social contact control
Number of subjects: 318
Study: 36535643

Group type: EXPERIMENTAL
Intervention: Plasma endotrophin levels in KTRs
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Plasma endotrophin levels before and after kidney transplantation
Number of subjects: 690
Study: 36535749

Group type: EXPERIMENTAL
Intervention: Higher mean IOP
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Peak IOP
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: IOP fluctuation (IOP SD)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Higher mean IOP in eyes with peak <18 mm Hg
Number of subjects: 62
Study: 36535765

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention with individualized exercise prescription and mHealth device providing heart rate-based just-in-time (JIT) feedback on PA intensity.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy aging education condition with a reading prescription and weekly quizzes.
Number of subjects: 44
Study: 36535779

Group type: EXPERIMENTAL
Intervention: Ticagrelor with Aspirin
Number of subjects: 6412

Group type: COMPARATOR
Intervention: Clopidogrel with Aspirin
Number of subjects: 6412
Study: 36535801

Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) during robotic bronchoscopy
Number of subjects: 20
Study: 36535990

Group type: EXPERIMENTAL
Intervention: Spectralis device (20° × 20°, 25 B-scans; 30° × 25°, 241 B-scans)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cirrus device (200 × 200 macular cube, 6 × 6 mm)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Less dense scans
Number of subjects: 200
Study: 36536016

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention package including monthly food vouchers for eggs, milk, semolina, sugar, and oil, multiple micronutrient powder (MNP), counseling on child feeding and handwashing.
Number of subjects: 412

Group type: COMPARATOR
Intervention: Regular government health communication alone (control).
Number of subjects: 412
Study: 36536050

Group type: EXPERIMENTAL
Intervention: Cardiovascular comorbidities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lung function (FEV1)
Number of subjects: 0
Study: 36536093

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA 50 units
Number of subjects: 520

Group type: COMPARATOR
Intervention: placebo (saltwater)
Number of subjects: 520

Group type: COMPARATOR
Intervention: onabotulinumtoxinA 20 units
Number of subjects: 520
Study: 36536114

Group type: EXPERIMENTAL
Intervention: Whey protein (0.25 g/kg fat free mass)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cricket protein (0.25 g/kg fat free mass)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pea protein (0.25 g/kg fat free mass)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cricket protein
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pea protein
Number of subjects: 50
Study: 36536249

Group type: EXPERIMENTAL
Intervention: Robotic tilt-table verticalization with functional electrical stimulation (FES)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Robotic tilt-table verticalization without functional electrical stimulation (FES)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional physiotherapy (CPT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: All groups (RTT with FES, RTT without FES, CPT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Verticalization/mobilization time
Number of subjects: 47
Study: 36536268

Group type: EXPERIMENTAL
Intervention: Multiple-choice applied knowledge measure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Role-play A (easier role-play)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Role-play B (more difficult role-play)
Number of subjects: 30
Study: 36536333

Group type: EXPERIMENTAL
Intervention: Collagen with PRP (Group A, n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Collagen alone (Group B, n=30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PRP alone (Group C, n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 90
Study: 36536364

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2 g per day for 8 weeks
Number of subjects: 0
Study: 36536403

Group type: EXPERIMENTAL
Intervention: CD3+ T cells prepared from cryopreserved PBMC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0